Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities

Conclusions: Our findings indicate that SPMS is associated with higher costs and more substantial HRQoL decrements than RRMS. These results highlight the substantial unmet need for effective treatments that can slow disease progression in patients with SPMS, which, in turn, would reduce the rate of HRQoL deterioration and increasing healthcare costs.PMID:33733976 | DOI:10.1080/03007995.2021.1904860

Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Jeremy Chataway Niamh Murphy Vivek Khurana Helen Schofield John Findlay Nicholas Adlard Source Type: research